Chemotherapy News and Research

Latest Chemotherapy News and Research

Few well performed studies address management of lymph node positive prostate cancer

Dr. Gregory Swanson and associates from the University of Texas, San Antonio Health Science Center reviews the data for various treatment options in patients with lymph node positive prostate cancer (CaP).

27 Jun 2006

Affymax and Takeda announce agreement for commercialization of Hematide for anemia

Affymax and Takeda Pharmaceutical Company have announced that the companies have entered into an exclusive global agreement to develop and commercialize Affymax's lead product candidate, Hematide, for the treatment of anemia.

27 Jun 2006

Injection may prevent infertility in men receiving cancer chemotherapy

It may be possible to protect the testes of cancer patients against the loss of fertility caused by chemotherapy.

20 Jun 2006

Burkitt lymphoma gene expression signature identified

An international research study involving the University of Nebraska Medical Center, the National Cancer Institute and 10 other institutions has successfully identified the gene expression signature for Burkitt lymphoma.

14 Jun 2006

Circulating bone-marrow derived cells do not contribute to egg formation

Ovulated egg cells, or oocytes, in adult female mice are not formed from germ cells in the blood or bone marrow.

14 Jun 2006

New test identifies patients who benefit from targeted cancer drugs

New lab test accurately identified patients who would benefit from treatment with the molecularly-targeted anti-cancer therapies gefitinib (Iressa, AstraZeneca) and erlotinib (Tarceva, Genentech).

13 Jun 2006

Terminally ill cancer patients continue to receive aggressive treatment at end of life

The increasing use of chemotherapy and intensive hospital treatment for cancer patients in their last two weeks of life continued at least into the late 1990s despite the growth of the hospice movement that emphasizes comforting personal bonds and controlling pain and discomfort

9 Jun 2006

Bortezomib extends lung cancer survival

Adding the new molecularly targeted agent bortezomib to a standard chemotherapy regimen of gemcitabine and carboplatin prolongs survival in patients with advanced non-small cell lung cancer, according to results from a phase II trial.

9 Jun 2006

Radionuclide therapy with chemotherapy effective in treating prostate cancer

A new treatment for prostate cancer may provide a distinct advantage over other conventional protocols and induce actual regression of the disease - not just relief from bone pain or a limited control of the disease.

9 Jun 2006

Liquorice compounds could be a key component for cheaper, more effective liver cancer treatment

Liquorice compounds could be a key component for cheaper, more effective liver cancer treatment, reports Chemistry & Industry magazine.

8 Jun 2006

Black women twice as likely to get aggressive breast cancer

New research has found that African-American women who contract breast cancer before reaching menopause are more than twice as likely as white women to have an aggressive, deadlier form of the disease.

8 Jun 2006

Sunitinib shows promise in treating metastatic renal cell cancer

A new study suggests that sunitinib is a promising agent for treatment of metastatic renal cell cancer, currently a disease without highly effective treatment options, according to an article in the June 7 issue of the Journal of the American Medical Association.

7 Jun 2006

Black women twice as likely to get aggressive breast cancer

7 Jun 2006

Black women have fewer breast cancers than white women, but their mortality is worse

For decades, researchers have tried to understand why breast cancer in younger black women is such a significant public health problem.

7 Jun 2006

Gleevec strangles drug-resistant, metastatic prostate cancer

A medication used to treat other types of cancer strangles drug-resistant, metastatic prostate cancer by cutting off its blood supply, researchers from The University of Texas M. D. Anderson Cancer Center report in the June 7 issue of the Journal of the National Cancer Institute.

7 Jun 2006

Trastuzumab results promising for HER-2 positive breast cancer patients

Researchers have shown that patients who receive trastuzumab at the same time as post-chemotherapy radiation treatments for HER-2 positive breast cancer have no more risk for major side effects or complications than those who do not receive the drug.

7 Jun 2006

Exercise is emerging as a new therapeutic weapon to tackle cancer

When individuals with breast or prostate cancer followed a moderate, home-based exercise program using resistance bands and walking, the patients had less fatigue during radiation treatments, greater strength and could walk farther and faster in only four weeks, researchers discovered in a pilot study.

7 Jun 2006

Long-term benefits of imatinib for patients newly diagnosed with chronic myelogenous leukemia

The overall survival of most people with chronic myelogenous leukemia (CML) treated with imatinib (Gleevec, STI-571) is extremely high and the relapse rate is quite low, according to new data from a study out of the Oregon Health & Science University Cancer Institute.

6 Jun 2006